August 5, 2019 / 9:26 PM / a month ago

Allergan settles generic Asacol delay claims for nearly $2.75 million

Allergan PLC has agreed to pay nearly $2.75 million to three union-sponsored health benefit plans to resolve a lawsuit alleging that a drugmaker the company now owns suppressed generic competition for its ulcerative colitis drug Asacol.

The settlements were disclosed in federal court in Boston on Friday, a day after an appellate court rejected the plaintiffs’ effort to challenge a judge’s decision to not consider their latest request to certify a class of purchasers of the drug.

To read the full story on WestlawNext Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below